Loading...
XNAS
XBIT
Market cap86mUSD
Jul 11, Last price  
2.83USD
1D
-4.39%
1Q
-13.72%
Jan 2017
-72.04%
IPO
-87.54%
Name

XBiotech Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-8.04%
Rev. gr., 5y
%
Revenues
0k
0000000043,997,00018,394,0004,010,00000
Net income
-39m
L+56.90%
-15,160,000-9,927,000-21,724,000-37,483,000-52,761,000-33,150,000-21,138,000668,629,000-11,221,000-17,414,000-32,900,000-24,557,000-38,531,000
CFO
-31m
L+65.36%
-11,634,000-8,908,000-11,700,000-33,308,000-46,015,000-33,649,000-16,537,000-18,270,000-65,149,00069,445,000-14,824,000-18,725,000-30,963,000
Dividend
Jul 15, 20212.5 USD/sh
Earnings
Aug 11, 2025

Profile

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
URL
http://www.xbiotech.com/
IPO date
Apr 15, 2015
Employees
84
Domiciled in
US
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,010
-78.20%
Cost of revenue
42,471
39,254
38,500
Unusual Expense (Income)
NOPBT
(42,471)
(39,254)
(34,490)
NOPBT Margin
Operating Taxes
32
244
(688)
Tax Rate
NOPAT
(42,503)
(39,498)
(33,802)
Net income
(38,531)
56.90%
(24,557)
-25.36%
(32,900)
88.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
200
5
BB yield
-0.17%
0.00%
Debt
Debt current
10,250
Long-term debt
Deferred revenue
Other long-term liabilities
1,720
1,669
1,576
Net debt
(162,427)
(200,023)
(217,478)
Cash flow
Cash from operating activities
(30,963)
(18,725)
(14,824)
CAPEX
(1,304)
(362)
(585)
Cash from investing activities
(1,304)
61,497
(63,892)
Cash from financing activities
10,450
(9)
FCF
(42,132)
(38,135)
(25,320)
Balance
Cash
172,677
200,023
217,478
Long term investments
Excess cash
172,677
200,023
217,278
Stockholders' equity
182,268
218,846
240,402
Invested Capital
21,561
20,492
24,646
ROIC
ROCE
EV
Common stock shares outstanding
30,461
30,438
30,439
Price
3.95
-1.25%
4.00
13.96%
3.51
-68.46%
Market cap
120,321
-1.18%
121,754
13.96%
106,842
-68.05%
EV
(42,106)
(78,269)
(110,636)
EBITDA
(40,726)
(37,510)
(31,876)
EV/EBITDA
1.03
2.09
3.47
Interest
807
902
Interest/NOPBT